IDEXX LABORATORIES INC /DE FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $4.3B |
| Gross margin | 61.8% |
| Operating income | $1.4B |
| Net income | $1.1B |
| Diluted EPS | $13.08 |
| Cash & equivalents | $180.1M |
| Total assets | $3.4B |
| Long-term debt | $450.0M |
Key takeaway
IDEXX posted $4.30 billion in revenue for 2025 with 61.8% gross margin and $1.06 billion net income, driven primarily by recurring diagnostic revenue (~79% of total).
🔒 4 more takeaways in the full analysis
Beneath the surface
Cash dropped sharply by about $108.2 million during the year (per the cash flow reconciliation), leaving only $180.1 million in cash against $450 million of long-term debt, indicating a net debt position of roughly $270 million despite strong profitability.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for IDXX.
Read the full analysis free Free account · 5 full analyses included · no card required